TOKYO, December 5, 2013 – On December 4, 2013, Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka), reached and entered into an agreement with Mitsui Fudosan Co., Ltd. (“Mitsui Fudosan”) to comprehensively transfer the owned real estate of Astellas and its group company Lotus Estate Co., Ltd. (“Lotus Estate”) to Mitsui Fudosan on March 31, 2014.
1. Purpose and schedule of the comprehensive transfer of owned real estate
(1) Purpose of the comprehensive transfer of owned real estate
Astellas will continue to implement its ongoing initiatives to transform the Company’s
organization and capabilities, enabling a resilient response to the rapidly-changing business
environment in pursuit of sustanable growth, while significantly strengthening our capabilities
by optimizing resource allocation to enhance the ability to generate innovative drugs.
As series of these initiatives, Astelas has reached this agreement with Mitusi Fudosan to make
a comprehensive transfer of the owned real estate of Astellas and Lotus Estate to Mitsui Fudosan.
(2) Schedule of the comprehensive transfer of owned real estate
December 4, 2013: Execution
March 31, 2014: Transfer (scheduled)
2. Method of the comprehensive transfer of owned real estate
Transfer of the owned real estate will be completed on March 31, 2014 (scheduled) as follows:
Real estate owned by Lotus Estate: Transfer of all shares in Lotus Estate
Real estate owned by Astellas: Transfer of real estate
